JOSEPH KHOURY to Neoplasms
This is a "connection" page, showing publications JOSEPH KHOURY has written about Neoplasms.
Connection Strength
1.021
-
Response to the Comments from the Groupe Francophone de Cytog?n?tique H?matologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors. Leukemia. 2023 05; 37(5):1170-1172.
Score: 0.136
-
Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS. Cytometry B Clin Cytom. 2023 01; 104(1):12-14.
Score: 0.134
-
Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications. Curr Hematol Malig Rep. 2019 10; 14(5):353-357.
Score: 0.107
-
Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018 02 01; 24(3):521-531.
Score: 0.093
-
The evolving potential of companion diagnostics. Scand J Clin Lab Invest Suppl. 2016; 245:S22-5.
Score: 0.086
-
Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med. 2015 Jan; 139(1):11-3.
Score: 0.077
-
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol. 2013 Aug; 87(16):8916-26.
Score: 0.069
-
The Journey to Improve the College of American Pathologists Cancer Biomarker Reporting Protocols. Arch Pathol Lab Med. 2024 Oct 01; 148(10):1105-1109.
Score: 0.038
-
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells. 2023 07 18; 12(14).
Score: 0.035
-
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023 05 23; 7(10):2000-2003.
Score: 0.034
-
Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
Score: 0.032
-
Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet. 2022 04; 262-263:23-29.
Score: 0.031
-
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304.
Score: 0.029
-
Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Curr Hematol Malig Rep. 2019 10; 14(5):358-367.
Score: 0.027
-
Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. Arch Pathol Lab Med. 2019 11; 143(11):1346-1363.
Score: 0.026
-
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
Score: 0.022
-
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
Score: 0.021
-
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15; 14(14):4572-83.
Score: 0.012
-
TAM kinases as regulators of cell death. Biochim Biophys Acta Mol Cell Res. 2021 05; 1868(6):118992.
Score: 0.007
-
Clinical significance of acquired loss of the X chromosome in bone marrow. Leuk Res. 2016 08; 47:109-13.
Score: 0.005